Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mahfuza Jan"'
Autor:
Elizabeth O. Hexner, Thelma S. Angeles, Pawel Dobrzanski, Cynthia Serdikoff, Martin Carroll, Mahfuza Jan, Bruce Ruggeri, Shi Yang, Stephen G. Emerson, Cezary R. Swider, Candy Robinson
Publikováno v:
Blood. 111:5663-5671
Recent studies have demonstrated that patients with myeloproliferative disorders (MPDs) frequently have acquired activating mutations in the JAK2 tyrosine kinase. A multikinase screen determined that lestaurtinib (formerly known as CEP-701) inhibits
Autor:
Matthew A. Curry, Zeqi Huang, Karen L. Milkiewicz, Benjamin J. Dugan, Pawel Dobrzanski, Bruce D. Dorsey, Eugen F. Mesaros, Bruce Ruggeri, Sheryl L. Meyer, Jennifer L. Mason, Mahfuza Jan, Mark S. Albom, Thelma S. Angeles, Diane E. Gingrich, Mark A. Ator, Allison L. Zulli, Lisa D. Aimone, Cynthia Serdikoff, Kevin J. Wells-Knecht
Publikováno v:
Journal of medicinal chemistry. 55(11)
Members of the JAK family of nonreceptor tyrosine kinases play a critical role in the growth and progression of many cancers and in inflammatory diseases. JAK2 has emerged as a leading therapeutic target for oncology, providing a rationale for the de
Autor:
Henry J. Breslin, James P. Finn, Lisa Saville, Jennifer L. Mason, Ted L. Underiner, Derek Dunn, Linda Weinberg, Jean Husten, Mahfuza Jan, Jay P. Theroff, Thelma S. Angeles, Teresa M. O'Kane, Karen L. Milkiewicz, Diane E. Gingrich, Tho V. Thieu, Lisa D. Aimone, Mark S. Albom, Craig A. Zificsak, Bruce D. Dorsey, Pawel Dobrzanski
Publikováno v:
Bioorganicmedicinal chemistry letters. 22(1)
The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression.
Autor:
Thelma Angeles, Bruce Ruggeri, Martin Carroll, Cynthia Serdikoff, Elizabeth O. Hexner, Candy Robinson, Cezary Swider, Mahfuza Jan, Stephen G. Emerson, Pawel Dobrzanski, Shi Yang
Publikováno v:
Blood. 108:3594-3594
Small molecule tyrosine kinase inhibitors have had dramatic clinical efficacy in chronic myelogenous leukemia. The identification of a specific activating mutation (V617F) in the gene encoding Janus Kinase 2 (JAK2) in a large proportion of patients w